Disease · MONDO_0018689

plasma cell leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. plasma cell leukemia. Diseases, record MONDO_0018689. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018689

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: plasma cell leukemia; Open Targets
Open Targets ID: MONDO_0018689; Open Targets
Other names: PCL, leukaemia plasmacytic, leukemia plasmacytic, plasmacytic leukaemia, plasmacytic leukemia; Open Targets
Disease Ontology: DOID:9513; Disease Ontology
MeSH: D007952; MeSH
NCI Thesaurus: C3180; NCI Thesaurus
Orphanet: ORPHA:454714; Orphanet
Highest stage of its drugs: Phase 2, for 12 of its 18 drugs, from ClinicalTrials.gov; Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	11	11	11	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
DARATUMUMAB	CHEMBL1743007	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CARFILZOMIB	CHEMBL451887	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ASPARAGINASE	CHEMBL2108989	Enzyme	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IXAZOMIB	CHEMBL2141296	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets65

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRM1	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	3	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	3	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	3	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
PSMA1	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5682	Drugs and targets
PSMA2	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5683	Drugs and targets
PSMA3	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5684	Drugs and targets
PSMA4	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5685	Drugs and targets
PSMA5	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5686	Drugs and targets
PSMA6	26S proteasome	3	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5687	Drugs and targets

1 to 10 of 65

See all 65 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00307086	Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants	Phase 2	30	2013-10-24	Multiple Myeloma, Plasma Cell Leukemia	BORTEZOMIB, MELPHALAN	Its record names the disease	ClinicalTrials.gov
NCT02547662	Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia	Phase 2	17	2022-05-23	Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma	DEXAMETHASONE, IXAZOMIB, POMALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00837200	Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies	Phase 2	13	2014-08-20	Non-hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma	ASPARAGINASE, DEXAMETHASONE, DOXORUBICIN	Its record names the disease	ClinicalTrials.gov
NCT03188172	MUK Nine b: OPTIMUM Treatment Protocol	Phase 2	95		Multiple Myeloma	BORTEZOMIB, CYCLOPHOSPHAMIDE, DARATUMUMAB, DEXAMETHASONE, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT01372540	Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia	Phase 1	76		Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma	CARFILZOMIB, FILANESIB	Its record names the disease	ClinicalTrials.gov
NCT07605416	Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial	Phase 2	74		Plasma Cell Leukemia	CARFILZOMIB, DARATUMUMAB, DEXAMETHASONE, LENALIDOMIDE, MELPHALAN, TECLISTAMAB	Its record names the disease	ClinicalTrials.gov
NCT00821249	A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma	Phase 1/2	55		Multiple Myeloma, Plasma Cell Leukemia	DEXAMETHASONE, FILANESIB	Its record names the disease	ClinicalTrials.gov
NCT01248923	A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma	Phase 1	55		Multiple Myeloma, Plasma Cell Leukemia	BORTEZOMIB, DEXAMETHASONE, FILANESIB	Its record names the disease	ClinicalTrials.gov
NCT05054478	Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation	Phase 2	29		Plasma Cell Leukemia	DARATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01553357	Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia	Phase 2	23		Primary Plasma Cell Leukemia	DEXAMETHASONE, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42705255	DERIVED	1	PubMed
37840055	DERIVED	1	PubMed
37315268	DERIVED	1	PubMed
35900614	DERIVED	1	PubMed
34826409	DERIVED	1	PubMed
33357481	DERIVED	1	PubMed
32710011	DERIVED	1	PubMed
28817190	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018689

GET https://conductscience.org/api/diseases/v1/MONDO_0018689/targets?page=2

API reference For AI assistants